I'm a guy who likes to give advice. I'd like to believe that, over the years, I've mellowed from coming across as a know-it-all to becoming a person who gives advice back to pay off the good advice I've recieved.
Be that as it may, Friday marked an event that illustrates how easy it is for one to neglect one's own advice. I've been sharing a "hot tip" with the stock investing community for over four years regarding stem cell research companies. One of George W. Bush's earliest actions as president was to ban most stem cell research. It was as clear as clear could be to me that one day that policy would be reversed and a whole raft of companies specializing in this research would rise with the swelling tide of progress. On Friday, a West Coast company won FDA approval for the first-ever study of a treatment based on human embryonic stem cells. I have watched this company closely and have traded in and out of it several times in the last year.
When the announcement came out, the stock shot up over 50% between Friday and Monday. Was I already in this stock on Friday? No. Was I in any of the other stem cell stocks I've been watching for the last three years? No. I had recently moved my holdings to cash in the aftermath of the financial crisis, (a good move) but had unwisely allowed the other cares of this world to distract me from keeping tabs on the market.
This is a good lesson to learn: It's not enough to see an event coming, you have to be sure to set yourself up to benefit from it should your prediction come true. As Lao Tzu wrote in the Tao Te Ching, "People usually fail when they are on the verge of success. So give as much care to the end as to the beginning; then there will be no failure". How hard would it have been to bought on some shares in the days before President Obama's inauguration? Answer: not hard at all. So why didn't I take care of this in time? As my mentor, Jim Rohn, would put it, "It was also easy not to."
Luckily, I'm in on the secret that there is no lack of wonderful, exciting opportunities in life. I guess I feel the "missing" of this opportunity more strongly because I've been mentally invested in its eventuality for what seems like a long period of time. Practically speaking, the long term upswing for stem cell stocks in general will almost certainly dwarf the gains my favorite stock made on Friday and Monday. As the market would have it, the stock's price has pulled back on lower volume from it's lofty Monday highs and I have picked up a number of shares. All of this is well and good.
Nevertheless, I intend to be aboard the rocket beforehand the next time I forsee an inevitable blast off.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment